ReviewWorld journal of gastroenterology2015
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 72 citations in OpenAlex.
- Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.Scientific reports · 2018Trial
- Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease.Intestinal research · 2026Article
- Global Variability in the Management of Inflammatory Bowel Disease: Towards Context-Specific Strategies.Cureus · 2025Review
- The War in Gaza and Barriers to Inflammatory Bowel Disease Care.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- How Managed Entry Agreements Influence the Patients' Affordability to Biological Medicines-Bulgarian Example.Healthcare (Basel, Switzerland) · 2023Article
- Article
- Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis.Therapeutic advances in gastroenterology · 2023Review
- Effects of miR-939 and miR-376A on ulcerative colitis using a decoy strategy to inhibit NF-κB and NFAT expression.European journal of histochemistry : EJH · 2022Article
- Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study).Therapeutic advances in gastroenterology · 2021Article
- Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.BioMed research international · 2021Article
- Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.Inflammatory bowel diseases · 2021Article
- The introduction of the IBD Disk in Poland - a new tool for assessing disability in patients with inflammatory bowel disease.Przeglad gastroenterologiczny · 2020Article
- Observational
- Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice.Journal of clinical medicine · 2019Article
- Patient and general population values for luminal and perianal fistulising Crohn's disease health states.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia.Cost effectiveness and resource allocation : C/E · 2019Article
- Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?Frontiers in pharmacology · 2019Review
- Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
- Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price.International journal of clinical pharmacy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological drugs opened up new horizons in the management of inflammatory bowel diseases (IBD). This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European (CEE) countries, namely Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovakia. Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed. Moreover, we provide an estimation on prevalence of IBD as well as biological treatment rates. In all countries with the exception of Romania, lower biological treatment rates were observed in ulcerative colitis (UC) compared to Crohn's disease despite the higher prevalence of UC. Great heterogeneity (up to 96-fold) was found in access to biologicals across the CEE countries. Poland, Bulgaria, Romania and the Baltic States are lagging behind Hungary, Slovakia and the Czech Republic in their access to biologicals. Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria, Latvia, Lithuania, and Poland, but association with other possible determinants (differences in prevalence and incidence, price of biologicals, total expenditure on health, geographical access, and cost-effectiveness results) was not proven. We assume, nevertheless, that health deterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD. In conclusion, access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors, drug prices or total health expenditure. Changes in reimbursement policy could contribute to better access to biologicals in some countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.